Ever-Changing Treatment Landscape of Aggressive B-Cell Lymphoma
Jason Westin, MD, MS, FACP, discusses recent developments in novel agents to treat and target aggressive lymphomas.
Sitravatinib Plus Tislelizumab Elicits Antitumor Activity in PD-L1+ Advanced NSCLC
Sitravatinib plus tislelizumab showed a confirmed investigator-assessed overall response rate of 30.4% in PD-L1–positive, treatment-naïve, locally advanced or metastatic squamous non–small cell lung cancer.
Westin Evaluates Management of DLBCL With CAR T-Cell Therapy
During a Targeted Oncology Case-Based Peer Perspectives virtual event, Jason Westin, MD, MS, evaluated the management of a 63-year-old patient with diffuse large B-cell lymphoma.
Current Treatment Options for DLBCL Besides R-CHOP Chemotherapy
Jason Westin, MD, MS, FACP, discusses the current treatment options for patients with diffuse large B-cell lymphoma that are available besides rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone.
2 Commerce Drive Cranbury, NJ 08512